Barlow Wealth Partners LLC Acquires 1,236 Shares of McKesson Corporation $MCK

Barlow Wealth Partners LLC grew its holdings in shares of McKesson Corporation (NYSE:MCK) by 7.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,123 shares of the company’s stock after buying an additional 1,236 shares during the quarter. McKesson accounts for approximately 1.5% of Barlow Wealth Partners LLC’s holdings, making the stock its 28th biggest holding. Barlow Wealth Partners LLC’s holdings in McKesson were worth $13,973,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MCK. State Street Corp increased its stake in McKesson by 0.9% during the third quarter. State Street Corp now owns 5,750,519 shares of the company’s stock worth $4,447,110,000 after acquiring an additional 51,510 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of McKesson by 3.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,681,321 shares of the company’s stock valued at $2,071,428,000 after purchasing an additional 90,948 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in shares of McKesson by 5.6% in the 3rd quarter. Alliancebernstein L.P. now owns 2,394,699 shares of the company’s stock worth $1,850,001,000 after purchasing an additional 126,684 shares during the period. Northern Trust Corp boosted its holdings in shares of McKesson by 0.4% in the 3rd quarter. Northern Trust Corp now owns 1,532,856 shares of the company’s stock worth $1,184,193,000 after purchasing an additional 6,613 shares during the period. Finally, Boston Partners increased its position in shares of McKesson by 6.7% during the 3rd quarter. Boston Partners now owns 1,330,953 shares of the company’s stock valued at $1,027,569,000 after purchasing an additional 83,357 shares during the last quarter. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Insider Buying and Selling

In other news, Director Maria Martinez sold 349 shares of McKesson stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $939.87, for a total transaction of $328,014.63. Following the completion of the sale, the director owned 301 shares of the company’s stock, valued at approximately $282,900.87. The trade was a 53.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the business’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $955.00, for a total value of $313,240.00. The SEC filing for this sale provides additional information. Insiders sold 3,868 shares of company stock worth $3,743,820 over the last 90 days. Corporate insiders own 0.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Leerink Partners restated an “outperform” rating and issued a $1,085.00 price target on shares of McKesson in a research report on Thursday, March 5th. Barclays boosted their price objective on shares of McKesson from $960.00 to $1,050.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Evercore restated an “outperform” rating on shares of McKesson in a report on Thursday, March 5th. Wells Fargo & Company lifted their price target on shares of McKesson from $914.00 to $925.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 5th. Finally, Mizuho upped their price target on shares of McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a report on Thursday, February 5th. Thirteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, McKesson currently has an average rating of “Moderate Buy” and an average price target of $960.93.

McKesson Stock Up 0.0%

MCK opened at $860.41 on Monday. The business has a fifty day moving average of $907.62 and a 200 day moving average of $840.69. The stock has a market cap of $105.39 billion, a P/E ratio of 24.75, a PEG ratio of 1.38 and a beta of 0.38. McKesson Corporation has a 52-week low of $637.00 and a 52-week high of $999.00.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping the consensus estimate of $9.19 by $0.15. The business had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period last year, the company earned $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Equities analysts anticipate that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be issued a dividend of $0.82 per share. The ex-dividend date is Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson’s dividend payout ratio (DPR) is presently 9.43%.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.